Summary
Pfizer Inc. filed an 8-K on April 28, 2010, reporting on the outcomes of its Annual Meeting of Shareholders held on April 22, 2010. The meeting focused on several key proposals, including the election of directors, ratification of independent auditors, executive compensation, and by-law amendments. The results indicate strong shareholder support for the company's slate of directors and its chosen auditor, KPMG LLP, as well as approval for the executive compensation policies and a by-law amendment to lower the threshold for calling special meetings. Notably, shareholders voted against a specific shareholder proposal concerning stock options. The overwhelming approval for most management-backed proposals suggests a general alignment between the board and its shareholders on governance and executive pay during this period. Investors should note the substantial shareholder participation and voting margins, which reflect a high level of engagement.
Key Highlights
- 1All director nominees were overwhelmingly elected for one-year terms, with strong "For" votes ranging from over 5.1 billion to over 5.3 billion.
- 2The appointment of KPMG LLP as Pfizer's independent registered public accounting firm for 2010 was ratified with significant shareholder approval (over 6.3 billion votes for).
- 3Shareholders approved, on an advisory basis, Pfizer's executive compensation policies and procedures for its named executive officers, with over 6.1 billion votes in favor.
- 4An amendment to the by-laws to reduce the percentage of shares required for shareholders to call special meetings was approved, with over 6.1 billion votes for.
- 5A shareholder proposal regarding stock options was not approved, receiving only approximately 224 million votes for compared to over 5.2 billion against.
- 6High levels of shareholder participation were evident across all proposals, with substantial numbers of votes cast and a significant amount of broker non-votes on director elections.